Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 905-908

  Bodmer, N ^a,b   Walters, D K ^b   Fuchs, B ^b,c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antifolate; Methotrexate; Osteosarcoma; Pemetrexed

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; IMMUNOBLOTTING; METHOTREXATE; OSTEOSARCOMA; THYMIDYLATE SYNTHASE;

EID: 40449108220     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21236     Document Type: Article

References (19)

1. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006.
2. McGuire JJ. Anticancer antifolates: Current status and future directions. Curr Pharm Des 2003;9:2593-2613.
3. Jaffe N. Osteogenic sarcoma: State of the art with high-dose methotrexate treatment. Clin Orthop Relat Res 1976;120:95-102.
4. Rollins KD, Lindley C. Pemetrexed: A multitargeted antifolate. Clin Ther 2005;27:1343-1382.
5. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006;24:37-77.
6. Adjei AA. Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 2006;17 Suppl 5:v29-v32.
7. Teicher BA, Alvarez E, Liu P, et al. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26:55-62.
8. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000;6:1016-1023.
9. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
10. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-3676.
11. Eismann U, Oberschmidt O, Ehnert M, et al. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors. Int J Clin Pharmacol Ther 2005;43:567-569.
12. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004;15:151-160.
13. Li W, Fan J, Hochhauser D, et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci U S A 1995;92:10436-10440.
14. Kim JH, Lee KW, Jung Y, et al. Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005;96:365-371.
15. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999;44:427-432.
16. Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179.
17. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes; correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-471.
18. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
19. van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5:643-654.